keyword
MENU ▼
Read by QxMD icon Read
search

Rotigotine

keyword
https://www.readbyqxmd.com/read/27883297/patients-perception-of-parkinson-s-disease-associated-pain-following-initiation-of-rotigotine-a-multicenter-non-interventional-study
#1
Lars Timmermann, Christian Oehlwein, Gerhard Ransmayr, Holger Fröhlich, Edgar Will, Hanna Schroeder, Thomas Lauterbach, Lars Bauer, Jan Kassubek
OBJECTIVES: To evaluate Parkinson's disease (PD)-associated pain as perceived by the patients (subjective characterization), and how this may change following initiation of rotigotine transdermal patch. METHODS: SP1058 was a non-interventional study conducted in routine clinical practice in Germany and Austria in patients experiencing PD-associated pain (per the physician's assessment). Data were collected at baseline (ie, before rotigotine initiation) and at a routine visit after ≥25 days (-3 days allowed) of treatment on a maintenance dose of rotigotine (end of study [EoS])...
November 24, 2016: Postgraduate Medicine
https://www.readbyqxmd.com/read/27870257/higher-levels-of-apomorphine-and-rotigotine-prescribing-reduce-overall-secondary-healthcare-costs-in-parkinson-s-disease
#2
A H Heald, M Livingston, M Stedman, Z Wyrko
BACKGROUND: Parkinson's disease (PD) affects around 100,000 people in England. A number of non-oral therapies can improve both the quality of life and reduce patient needs for health and social care. However, these can be relatively expensive at £2000-£10,000 per year per patient. Our aim was to examine how prescribing of these agents relates to secondary care costs. METHODS: Using practice level primary care prescribing data and hospital episode statistical data in England, we investigated the relation between general practitioner prescriptions of apomorphine injections/rotigotine patches and the secondary care costs accrued for their diagnosed PD patients for 2011-2014...
November 2016: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/27856776/practice-guideline-summary-treatment-of-restless-legs-syndrome-in-adults-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology
#3
John W Winkelman, Melissa J Armstrong, Richard P Allen, K Ray Chaudhuri, William Ondo, Claudia Trenkwalder, Phyllis C Zee, Gary S Gronseth, David Gloss, Theresa Zesiewicz
OBJECTIVE: To make evidence-based recommendations regarding restless legs syndrome (RLS) management in adults. METHODS: Articles were classified per the 2004 American Academy of Neurology evidence rating scheme. Recommendations were tied to evidence strength. RESULTS AND RECOMMENDATIONS: In moderate to severe primary RLS, clinicians should consider prescribing medication to reduce RLS symptoms. Strong evidence supports pramipexole, rotigotine, cabergoline, and gabapentin enacarbil use (Level A); moderate evidence supports ropinirole, pregabalin, and IV ferric carboxymaltose use (Level B)...
November 16, 2016: Neurology
https://www.readbyqxmd.com/read/27810181/a-method-to-switch-from-oral-dopamine-agonists-to-rotigotine-in-patients-with-restless-legs-syndrome-and-mild-augmentation
#4
John W Winkelman, Susan E Mackie, Leslie A Mei, Samuel Platt, Laura Schoerning
BACKGROUND: We examined the short- and long-term efficacy and tolerability of a cross-titration algorithm from oral dopamine agonists to the rotigotine transdermal patch in patients dissatisfied with their restless legs syndrome (RLS) treatment, predominantly with mild augmentation. METHODS: Patients with RLS (n = 20) were recruited at a single site. The cross-titration consisted of decreasing oral dopaminergic agents (ropinirole by 1 mg or pramipexole by 0...
August 2016: Sleep Medicine
https://www.readbyqxmd.com/read/27796464/ergot-and-non-ergot-dopamine-agonists-and-heart-failure-in-patients-with-parkinson-s-disease
#5
François Montastruc, Florence Moulis, Mélanie Araujo, Leila Chebane, Olivier Rascol, Jean-Louis Montastruc
PURPOSE: Some studies have suggested a potential risk of heart failure in patients with Parkinson's disease receiving dopamine (DA) agonists. However, the results are conflicting. We used VigiBase®, the World Health Organization (WHO) Global Individual Case Safety Reports (ICSRs) database, to investigate a potential signal strengthening of heart failure with DA agonists in Parkinsonian patients older than 45 years. METHODS: A case/non-case (disproportionality) analysis was performed in Vigibase® using ICSRs registered between 1978 and May 2016...
October 27, 2016: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27726069/an-observational-clinical-and-video-polysomnographic-study-of-the-effects-of-rotigotine-in-sleep-disorder-in-parkinson-s-disease
#6
Yan Wang, Yue-Chang Yang, Dan-Mei Lan, Hui -Juan Wu, Zhong-Xin Zhao
PURPOSE: Sleep disturbance is common in Parkinson's disease (PD) and negatively impacts quality of life. There is little data on how dopamine agonists influence nocturnal sleep in PD, particularly in sleep laboratory data to measure sleep parameters and their changes objectively. The goal of this open-label study was to objectively evaluate the effect of rotigotine on sleep in PD patients by video-polysomnographic methods. METHODS: A total of 25 PD patients with complaints of nocturnal sleep impairment were enrolled...
October 11, 2016: Sleep & Breathing, Schlaf & Atmung
https://www.readbyqxmd.com/read/27725534/transdermal-patch-of-rotigotine-attenuates-freezing-of-gait-in-patients-with-parkinson-s-disease-an-open-label-comparative-study-of-three-non-ergot-dopamine-receptor-agonists
#7
Ken Ikeda, Takehisa Hirayama, Takanori Takazawa, Kiyokazu Kawabe, Yasuo Iwasaki
Objective Parkinson's disease (PD) is characterized by the progressive degeneration of the nigrostriatal dopaminergic neurons. Rotigotine is a non-ergot dopamine receptor agonist (DA). Its transdermal patch maintains the effective concentrations for 24 hours. Freezing of gait (FOG) is a common and devastating symptom in PD patients. Little is known about therapeutic effects of rotigotine on FOG in PD patients. Herein we compared how three non-ergot DAs of rotigotine, pramipexole LA and ropinirole CR influence FOG, besides classical motor deficits in PD patients...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27629973/restless-bladder-in-an-elderly-woman-an-unusual-feature-or-a-variant-of-restless-legs-syndrome
#8
Keisuke Suzuki, Masayuki Miyamoto, Tomoyuki Uchiyama, Tomoyuki Miyamoto, Takeo Matsubara, Koichi Hirata
We herein report an elderly patient with a history of restless legs syndrome (RLS) who developed unpleasant sensations in the lower abdomen and perineum. The patient' s symptoms occurred during the evening and at rest and forced the patient to void, resulting in some symptom relief. Urological examinations and spinal magnetic resonance imaging findings were unremarkable. The adjunctive use of rotigotine resolved her symptoms. The symptoms were considered to be "restless bladder". Further studies are required to elucidate whether restless bladder is an identical condition to the clinical entities of other RLS variants or whether it represents an unusual feature of RLS...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27568909/effects-of-rotigotine-on-rem-sleep-behavior-disorder-in-parkinson-disease
#9
Yan Wang, Yuechang Yang, Huijuan Wu, Danmei Lan, Ying Chen, Zhongxin Zhao
STUDY OBJECTIVES: REM sleep behavior disorder (RBD) is a common manifestation of Parkinson disease (PD). In this study, we assessed the effects of rotigotine transdermal patch on RBD features in patients with PD. METHODS: In this prospective open-label study, eleven PD patients with untreated RBD were administered rotigotine patches for up to seven months to ameliorate their parkinsonism. The severities of their RBD symptoms before and after rotigotine therapy were evaluated through patient and bed partner interviews, a validated evaluation scale (REM sleep behavior disorder questionnaire-Hong Kong, RBDQ-HK), and blinded assessments based on video-polysomnographic (VPSG) measure...
October 15, 2016: Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine
https://www.readbyqxmd.com/read/27567886/efficacy-of-rotigotine-at-different-stages-of%C3%A2-parkinson-s-disease-symptom-severity-and-disability-a-post-hoc-analysis-according-to-baseline-hoehn-and-yahr-stage
#10
Nir Giladi, Anthony P Nicholas, Mahnaz Asgharnejad, Elisabeth Dohin, Franz Woltering, Lars Bauer, Werner Poewe
BACKGROUND: The efficacy of rotigotine has been demonstrated in studies of patients with early (i.e. not receiving levodopa) and advanced (i.e. not adequately controlled on levodopa; average 2.5 h/day in 'off' state) Parkinson's disease (PD). OBJECTIVE: To further investigate the efficacy of rotigotine transdermal patch across different stages of PD symptom severity and functional disability, according to baseline Hoehn and Yahr (HY) staging. METHODS: Post hoc analysis of six placebo-controlled studies of rotigotine in patients with early PD (SP506, SP512, SP513; rotigotine ≤8 mg/24 h) or advanced-PD (CLEOPATRA-PD, PREFER, SP921; rotigotine ≤16 mg/24 h)...
October 19, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27448485/rotigotine-may-improve-sleep-architecture-in-parkinson-s-disease-a-double-blind-randomized-placebo-controlled-polysomnographic-study
#11
Mariangela Pierantozzi, Fabio Placidi, Claudio Liguori, Maria Albanese, Paola Imbriani, Maria Grazia Marciani, Nicola Biagio Mercuri, Paolo Stanzione, Alessandro Stefani
BACKGROUND/OBJECTIVES: Growing evidence demonstrates that in Parkinson's Disease (PD) sleep disturbances are frequent and difficult to treat. Since the efficacy of rotigotine on sleep is corroborated by studies lacking polysomnography (PSG), this study explores the possible rotigotine-mediated impact on PSG parameters in PD patients. METHODS: This is a randomized, double-blind, placebo-controlled, parallel-group study to determine the efficacy of rotigotine vs placebo on PSG parameters in moderately advanced PD patients...
May 2016: Sleep Medicine
https://www.readbyqxmd.com/read/27448465/guidelines-for-the-first-line-treatment-of-restless-legs-syndrome-willis-ekbom-disease-prevention-and-treatment-of-dopaminergic-augmentation-a-combined-task-force-of-the-irlssg-eurlssg-and-the-rls-foundation
#12
Diego Garcia-Borreguero, Michael H Silber, John W Winkelman, Birgit Högl, Jacquelyn Bainbridge, Mark Buchfuhrer, Georgios Hadjigeorgiou, Yuichi Inoue, Mauro Manconi, Wolfgang Oertel, William Ondo, Juliane Winkelmann, Richard P Allen
A Task Force was established by the International Restless Legs Syndrome Study Group (IRLSSG) in conjunction with the European Restless Legs Syndrome Study Group (EURLSSG) and the RLS Foundation (RLS-F) to develop evidence-based and consensus-based recommendations for the prevention and treatment of long-term pharmacologic treatment of dopaminergic-induced augmentation in restless legs syndrome/Willis-Ekbom disease (RLS/WED). The Task Force made the following prevention and treatment recommendations: As a means to prevent augmentation, medications such as α2δ ligands may be considered for initial RLS/WED treatment; these drugs are effective and have little risk of augmentation...
May 2016: Sleep Medicine
https://www.readbyqxmd.com/read/27425586/impulse-control-disorder-related-behaviours-during-long-term-rotigotine-treatment-a-post-hoc-analysis
#13
A Antonini, K R Chaudhuri, B Boroojerdi, M Asgharnejad, L Bauer, F Grieger, D Weintraub
BACKGROUND AND PURPOSE: Dopamine agonists in Parkinson's disease (PD) are associated with impulse control disorders (ICDs) and other compulsive behaviours (together called ICD behaviours). The frequency of ICD behaviours reported as adverse events (AEs) in long-term studies of rotigotine transdermal patch in PD was evaluated. METHODS: This was a post hoc analysis of six open-label extension studies up to 6 years in duration. Analyses included patients treated with rotigotine for at least 6 months and administered the modified Minnesota Impulse Disorders Interview...
October 2016: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/27385523/allergic-contact-dermatitis-caused-by-rotigotine-in-a-transdermal-therapeutic-system
#14
Nadia Raison-Peyron, Bernard Guillot
No abstract text is available yet for this article.
August 2016: Contact Dermatitis
https://www.readbyqxmd.com/read/27343381/in-vivo-dopamine-agonist-properties-of-rotigotine-role-of-d1-and-d2-receptors
#15
Sandro Fenu, Elena Espa, Augusta Pisanu, Gaetano Di Chiara
Rotigotine acts in vitro as a full agonist of dopamine D1 receptors at concentrations almost superimposable to those at which it acts on D2 receptors. However in vivo evidence of the differences between the agonist activity of rotigotine at D1 receptors from that on the D2 receptors has not been provided yet. In order to test the ability of rotigotine to stimulate dopamine D1 and D2 receptors in vivo, we studied the effect of SCH39166 and eticlopride, selective dopamine D1 and D2/D3 receptor antagonists respectively, on rotigotine-induced contralateral turning behavior in 6-hydroxydopamine lesioned rats...
October 5, 2016: European Journal of Pharmacology
https://www.readbyqxmd.com/read/27324269/rotigotine-transdermal-patch-a-review-in-restless-legs-syndrome
#16
Karly P Garnock-Jones
Rotigotine transdermal patch (Leganto(®), Neupro(®)) is indicated for the treatment of restless legs syndrome (RLS); this article reviews the pharmacological properties of rotigotine transdermal patch and its clinical efficacy and tolerability in patients with RLS. The transdermal patch allows for a continuous, stable release of rotigotine (avoiding first-pass metabolism), which in turn leads to continuous receptor stimulation, believed to closely mimic physiological striatal dopamine receptor function. In short-term and 6-month studies, especially at the higher dosages of 2 and 3 mg/24 h, rotigotine transdermal patch was generally associated with a significantly greater improvement in IRLS total score and CGI-S total score than placebo, and rotigotine recipients were generally more likely to respond to treatment and enter remission...
July 2016: Drugs
https://www.readbyqxmd.com/read/27322571/evaluation-of-rotigotine-transdermal-patch-for-the-treatment-of-depressive-symptoms-in-patients-with-parkinson-s-disease
#17
Sun Ju Chung, Mahnaz Asgharnejad, Lars Bauer, Francisco Ramirez, Beomseok Jeon
OBJECTIVE: To evaluate the dopamine receptor agonist, rotigotine, for improving depressive symptoms in patients with Parkinson's disease (PD). METHODS: Patients were randomized 1:1 to rotigotine or placebo, titrated for ≤7 weeks, and maintained at optimal/maximum dose for 8-weeks. Primary efficacy variable: 17- item Hamilton Depression Rating Scale (HAM-D 17) total score change from baseline to end-of-maintenance. Secondary variables: changes in Beck Depression Inventory-II, Unified Parkinson's Disease Rating Scale (UPDRS) II (activities of daily living [ADL]) and III (motor) subscores, UPDRS II+III total, patient-rated Apathy Scale (AS), and Snaith-Hamilton Pleasure Scale...
August 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27279164/-continued-use-of-rotigotine-transdermal-patches-for-parkinson-disease
#18
Yuki Yasutaka, Shinsuke Fujioka, Hirotomo Shibaguchi, Osamu Imakyure, Atsushi Washiyama, Yoshio Tsuboi, Koujiro Futagami
Transdermal patches containing rotigotine, a dopamine agonist (DA) for treatment of Parkinson disease, continuously exert stable effects when applied once daily. Therefore, they are expected to reduce the patient burdens due to complications such as wearing-off and dysphagia. However, dosing is occasionally reduced or discontinued after application because of several reasons such as skin reactions or unsatisfactory efficacy. To identify the risk factors involved in the reduced or discontinued use of rotigotine patches, a retrospective study was conducted with reference to the medical records of patients with Parkinson disease who received rotigotine patches in our hospital...
June 2016: Brain and Nerve, Shinkei Kenkyū No Shinpo
https://www.readbyqxmd.com/read/27276074/-perioperative-management-of-pd-patients
#19
H Reichmann
Both patients and caregivers but also treating physicians are concerned about complications along with surgical interventions. A major problem is abrupt cessation of anti-Parkinson medication, which leads to manifold disturbances, sometimes even to an akinetic crisis. There are several means to guarantee continuous dopaminergic stimulation even in patients that are not allowed to take medication orally before they undergo surgery. Amongst others rectally applied levodopa, amantadine infusions, and especially the use of a rotigotine patch are good means to overcome oral intake...
July 2016: Fortschritte der Neurologie-Psychiatrie
https://www.readbyqxmd.com/read/27275128/preparation-and-evaluation-of-rotigotine-loaded-implant-for-the-treatment-of-parkinson-s-disease-and-its-evolution-study
#20
Aiping Wang, Yanxiang Liu, Rongcai Liang, Xuemei Zhang, Kaoxiang Sun, Zimei Wu, Wanhui Liu
PURPOSE: To develop rotigotine-loaded implants (RI) to achieve continuous release of rotigotine for long duration for the treatment of Parkinson's disease (PD). METHODS: RI was prepared by hot-melt extrusion method using poly (lactide-co-glycolide) (PLGA) as the matrix. In vitro drug release was optimized by drug loading, melting temperature during preparing process and additives. The surface and internal morphology of RI was imaged by SEM. The in vivo release profile of RI was investigated on rat...
May 2016: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
keyword
keyword
56686
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"